Lv22
140 积分 2025-07-18 加入
Target identification and assessment in the era of AI
6小时前
待确认
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies
1天前
已完结
Allometric principles for interspecies extrapolation in toxicological risk assessment—empirical investigations
15天前
已完结
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
28天前
已完结
Colibactin‐positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer
29天前
已完结
Abstract CT174: Unlocking endocrine resistance: Co-targeting KAT6 and ER with prifetrastat (PF-07248144) and fulvestrant drives tumor and ctDNA response in ER+/HER2− metastatic breast cancer
1个月前
已关闭
An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII
1个月前
已完结
Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges
1个月前
已完结
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
1个月前
已完结
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies
1个月前
已完结
皖公网安备34019202002308
